seekingalpha.com
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
biote Corp.BTMDNASDAQ
Loading
Latest News
Loading news...
zacks.com
biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago.
businesswire.com
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Over the past twelve months, Biote has focused on our strategic priorities which are designed to drive sustainable profitable growth and create long-term value for stockholders,” said Bret Christensen, Biote's Chief.
businesswire.com
Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conferenc.
defenseworld.net
Head to Head Comparison: Agilent Technologies (NYSE:A) vs. biote (NASDAQ:BTMD)
biote (NASDAQ: BTMD - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations. Profitability This table compares biote and Agilent Technologies' net
defenseworld.net
biote Corp. $BTMD Stock Position Lessened by Bandera Partners LLC
Bandera Partners LLC decreased its position in shares of biote Corp. (NASDAQ: BTMD) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,283,791 shares of the company's stock after selling 151,844 shares during the period. biote accounts for 4.1%
seekingalpha.com
biote Corp. (BTMD) Q3 2025 Earnings Call Transcript
biote Corp. ( BTMD ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bret Christensen - CEO & Director Robert Peterson - CFO and Chief Business Officer Conference Call Participants Szymon Serowiecki Kaumil Gajrawala - Jefferies LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Jeff Van Sinderen - B. Riley Securities, Inc., Research Division Jungwon Kim - TD Cowen, Research Division George Kelly - ROTH Capital Partners, LLC, Research Division Presentation Operator Good day, and welcome to the Biote Third Quarter 2025 Earnings Conference Call.
zacks.com
biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates
biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago.
businesswire.com
Biote Reports Third Quarter 2025 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the third quarter ended September 30, 2025. “When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre.
businesswire.com
Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call m.
seekingalpha.com
Restructuring At Biote Will Drive Greater Growth And Profitability
I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company's vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance.
seekingalpha.com
biote Corp. (BTMD) Q2 2025 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bret Christensen - CEO & Director Robert C. Peterson - Chief Financial Officer Conference Call Participants Jeffrey Wallin Van Sinderen - B.
zacks.com
biote Corp. (BTMD) Tops Q2 Earnings Estimates
biote Corp. (BTMD) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.14 per share a year ago.
businesswire.com
Biote Reports Second Quarter 2025 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2025. “Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable.
zacks.com
Is biote Corp. (BTMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
businesswire.com
Biote Names Rich Barrera to Board of Directors
IRVING, Texas--(BUSINESS WIRE)--biote Corp.(NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. “We are pleased to welcome Rich Barrera to Biote's Board of Directors,” said Marc Beer, Executive Chairman of Biote. “Rich has a distinguished background as an investment professional, founding R.
seekingalpha.com
biote Corp. (BTMD) Q1 2025 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Conference Call Participants Kaumil Gajrawala - Jefferies Les Sulewski - Truist Jonna Kim - TD Cowen Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Operator Hello, and welcome to the biote First Quarter 2025 Earnings Conference Call.
zacks.com
Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates
Biote Corp. (BTMD) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.23 per share a year ago.
businesswire.com
Biote Announces Purchase of Shares by Directors and CEO
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote's common stock, acquiring an aggregate of approximately 260,000 shares. Marc Beer, Biote Executive Chairman, said, "These share purchase.
seekingalpha.com
biote Corp. (BTMD) Q4 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Corporate Participants Szymon Serowiecki - Investor Relations Mark Beard - Executive Chairman Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conference Call.